Literature DB >> 25453753

Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor.

Nicholas J Bessman1, Atrish Bagchi2, Kathryn M Ferguson2, Mark A Lemmon3.   

Abstract

The epidermal growth factor receptor (EGFR) plays pivotal roles in development and is mutated or overexpressed in several cancers. Despite recent advances, the complex allosteric regulation of EGFR remains incompletely understood. Through efforts to understand why the negative cooperativity observed for intact EGFR is lost in studies of its isolated extracellular region (ECR), we uncovered unexpected relationships between ligand binding and receptor dimerization. The two processes appear to compete. Surprisingly, dimerization does not enhance ligand binding (although ligand binding promotes dimerization). We further show that simply forcing EGFR ECRs into preformed dimers without ligand yields ill-defined, heterogeneous structures. Finally, we demonstrate that extracellular EGFR-activating mutations in glioblastoma enhance ligand-binding affinity without directly promoting EGFR dimerization, suggesting that these oncogenic mutations alter the allosteric linkage between dimerization and ligand binding. Our findings have important implications for understanding how EGFR and its relatives are activated by specific ligands and pathological mutations.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25453753      PMCID: PMC4254573          DOI: 10.1016/j.celrep.2014.10.010

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  45 in total

1.  The membrane-proximal intracellular domain of the epidermal growth factor receptor underlies negative cooperativity in ligand binding.

Authors:  Sangeeta Adak; Katherine S Yang; Jennifer Macdonald-Obermann; Linda J Pike
Journal:  J Biol Chem       Date:  2011-11-08       Impact factor: 5.157

2.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  Quantitation of the effect of ErbB2 on epidermal growth factor receptor binding and dimerization.

Authors:  Yu Li; Jennifer Macdonald-Obermann; Corey Westfall; David Piwnica-Worms; Linda J Pike
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

4.  Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor.

Authors:  Li-Zhi Mi; Chafen Lu; Zongli Li; Noritaka Nishida; Thomas Walz; Timothy A Springer
Journal:  Nat Struct Mol Biol       Date:  2011-08-07       Impact factor: 15.369

5.  A single ligand is sufficient to activate EGFR dimers.

Authors:  Ping Liu; Thomas E Cleveland; Samuel Bouyain; Patrick O Byrne; Patti A Longo; Daniel J Leahy
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-14       Impact factor: 11.205

6.  Oncogenic ERBB3 mutations in human cancers.

Authors:  Bijay S Jaiswal; Noelyn M Kljavin; Eric W Stawiski; Emily Chan; Chaitali Parikh; Steffen Durinck; Subhra Chaudhuri; Kanan Pujara; Joseph Guillory; Kyle A Edgar; Vasantharajan Janakiraman; Rolf-Peter Scholz; Krista K Bowman; Maria Lorenzo; Hong Li; Jiansheng Wu; Wenlin Yuan; Brock A Peters; Zhengyan Kan; Jeremy Stinson; Michelle Mak; Zora Modrusan; Charles Eigenbrot; Ron Firestein; Howard M Stern; Krishnaraj Rajalingam; Gabriele Schaefer; Mark A Merchant; Mark X Sliwkowski; Frederic J de Sauvage; Somasekar Seshagiri
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

7.  Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor.

Authors:  Chafen Lu; Li-Zhi Mi; Thomas Schürpf; Thomas Walz; Timothy A Springer
Journal:  J Biol Chem       Date:  2012-09-17       Impact factor: 5.157

8.  Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

Authors:  Igor Vivanco; H Ian Robins; Daniel Rohle; Carl Campos; Christian Grommes; Phioanh Leia Nghiemphu; Sara Kubek; Barbara Oldrini; Milan G Chheda; Nicolas Yannuzzi; Hui Tao; Shaojun Zhu; Akio Iwanami; Daisuke Kuga; Julie Dang; Alicia Pedraza; Cameron W Brennan; Adriana Heguy; Linda M Liau; Frank Lieberman; W K Alfred Yung; Mark R Gilbert; David A Reardon; Jan Drappatz; Patrick Y Wen; Kathleen R Lamborn; Susan M Chang; Michael D Prados; Howard A Fine; Steve Horvath; Nian Wu; Andrew B Lassman; Lisa M DeAngelis; William H Yong; John G Kuhn; Paul S Mischel; Minesh P Mehta; Timothy F Cloughesy; Ingo K Mellinghoff
Journal:  Cancer Discov       Date:  2012-03-31       Impact factor: 39.397

9.  Architecture and membrane interactions of the EGF receptor.

Authors:  Anton Arkhipov; Yibing Shan; Rahul Das; Nicholas F Endres; Michael P Eastwood; David E Wemmer; John Kuriyan; David E Shaw
Journal:  Cell       Date:  2013-01-31       Impact factor: 41.582

10.  Conformational coupling across the plasma membrane in activation of the EGF receptor.

Authors:  Nicholas F Endres; Rahul Das; Adam W Smith; Anton Arkhipov; Erika Kovacs; Yongjian Huang; Jeffrey G Pelton; Yibing Shan; David E Shaw; David E Wemmer; Jay T Groves; John Kuriyan
Journal:  Cell       Date:  2013-01-31       Impact factor: 41.582

View more
  34 in total

1.  Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.

Authors:  Zev A Binder; Amy Haseley Thorne; Spyridon Bakas; E Paul Wileyto; Michel Bilello; Hamed Akbari; Saima Rathore; Sung Min Ha; Logan Zhang; Cole J Ferguson; Sonika Dahiya; Wenya Linda Bi; David A Reardon; Ahmed Idbaih; Joerg Felsberg; Bettina Hentschel; Michael Weller; Stephen J Bagley; Jennifer J D Morrissette; MacLean P Nasrallah; Jianhui Ma; Ciro Zanca; Andrew M Scott; Laura Orellana; Christos Davatzikos; Frank B Furnari; Donald M O'Rourke
Journal:  Cancer Cell       Date:  2018-07-09       Impact factor: 31.743

2.  Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope.

Authors:  Laura Orellana; Amy H Thorne; Rafael Lema; Johan Gustavsson; Alison D Parisian; Adam Hospital; Tiago N Cordeiro; Pau Bernadó; Andrew M Scott; Isabelle Brun-Heath; Erik Lindahl; Webster K Cavenee; Frank B Furnari; Modesto Orozco
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-26       Impact factor: 11.205

Review 3.  Membrane receptor activation mechanisms and transmembrane peptide tools to elucidate them.

Authors:  Justin M Westerfield; Francisco N Barrera
Journal:  J Biol Chem       Date:  2019-12-25       Impact factor: 5.157

Review 4.  Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials.

Authors:  Aarti Bhatia; Barbara Burtness
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

5.  Growth Factor Identity Is Encoded by Discrete Coiled-Coil Rotamers in the EGFR Juxtamembrane Region.

Authors:  Amy Doerner; Rebecca Scheck; Alanna Schepartz
Journal:  Chem Biol       Date:  2015-06-18

6.  Receptor Level Mechanisms Are Required for Epidermal Growth Factor (EGF)-stimulated Extracellular Signal-regulated Kinase (ERK) Activity Pulses.

Authors:  Breanne Sparta; Michael Pargett; Marta Minguet; Kevin Distor; George Bell; John G Albeck
Journal:  J Biol Chem       Date:  2015-08-24       Impact factor: 5.157

7.  Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.

Authors:  Oleksii S Rukhlenko; Fahimeh Khorsand; Aleksandar Krstic; Jan Rozanc; Leonidas G Alexopoulos; Nora Rauch; Keesha E Erickson; William S Hlavacek; Richard G Posner; Silvia Gómez-Coca; Edina Rosta; Cheree Fitzgibbon; David Matallanas; Jens Rauch; Walter Kolch; Boris N Kholodenko
Journal:  Cell Syst       Date:  2018-07-11       Impact factor: 10.304

Review 8.  Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease.

Authors:  Mitchell I Parker; Anna S Nikonova; Danlin Sun; Erica A Golemis
Journal:  Cell Signal       Date:  2019-12-09       Impact factor: 4.315

9.  EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics.

Authors:  Daniel M Freed; Nicholas J Bessman; Anatoly Kiyatkin; Emanuel Salazar-Cavazos; Patrick O Byrne; Jason O Moore; Christopher C Valley; Kathryn M Ferguson; Daniel J Leahy; Diane S Lidke; Mark A Lemmon
Journal:  Cell       Date:  2017-10-05       Impact factor: 41.582

10.  Allosteric regulation of epidermal growth factor (EGF) receptor ligand binding by tyrosine kinase inhibitors.

Authors:  Jennifer L Macdonald-Obermann; Linda J Pike
Journal:  J Biol Chem       Date:  2018-07-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.